MOTS-C: The Mitochondria-Derived Peptide Rewriting Metabolic Research

MOTS-C is encoded in mitochondrial DNA — not nuclear DNA — making it one of the most biologically native peptides under clinical investigation. Here is what the research shows about its role in metabolic health and longevity.

By UAE Peptide Clinic Research Desk

Most peptides are synthesised in a laboratory and administered to mimic or amplify the body's own signalling molecules. MOTS-C is different. It is produced naturally within your own mitochondria — the energy-generating structures inside every cell — making it one of the most biologically native peptides currently under clinical investigation. For those interested in metabolic health and longevity, it represents a genuinely new category of research.

What Is MOTS-C?

MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a peptide encoded not in the cell's nuclear DNA but in mitochondrial DNA. Discovered in 2015 by researchers at the University of Southern California, it is classified as a mitochondria-derived peptide (MDP) — a family of signalling molecules that communicate the metabolic state of the mitochondria to the rest of the cell and, via circulation, to distant tissues.

Unlike conventional peptide hormones, MOTS-C appears to function as a metabolic regulator, shifting how cells process glucose and fatty acids depending on energetic demand. Circulating MOTS-C levels have been found to decline with age, paralleling the broader pattern of mitochondrial dysfunction seen in ageing research.

What the Research Shows

The published science on MOTS-C is preclinical, primarily conducted in rodent models, but the findings are directionally consistent across independent research groups. Key areas of investigation include:

• Insulin sensitivity: MOTS-C administration improved insulin-stimulated glucose uptake in skeletal muscle in multiple murine studies, acting through AMPK activation — one of the body's primary metabolic regulators.
• Visceral adiposity: In diet-induced obesity models, MOTS-C reduced fat accumulation, particularly visceral fat, without significant changes to food intake.
• Exercise mimicry: Research published in Cell Metabolism (2019) found that MOTS-C levels rise in response to physical exercise and that exogenous MOTS-C produced exercise-like metabolic benefits in sedentary mice, leading to the label 'exercise mimetic'.
• Longevity correlation: Population studies have found higher circulating MOTS-C in centenarians compared to younger elderly adults, raising the hypothesis that it may be a marker — or mediator — of metabolic longevity.

MOTS-C and the Ageing Mitochondria

The decline in MOTS-C with age is part of a broader story of mitochondrial deterioration. As mitochondria become less efficient, the signalling they produce — including MOTS-C — diminishes. This creates a feedback loop: lower MOTS-C means reduced AMPK activity, reduced glucose clearance, and greater reliance on less efficient metabolic pathways. The question researchers are exploring is whether exogenous MOTS-C can interrupt this cycle and restore some of the metabolic flexibility that is characteristic of younger physiology.

MOTS-C is not an external pharmaceutical imposing a drug effect. It is a signal the body already produces — one that research suggests diminishes with age. Replacing it is a different conceptual category from conventional pharmacology.

Clinical Considerations in Practice

Because MOTS-C research is still in preclinical and early translational phases, no standardised human dosing protocols have been established in published literature. Human trials are underway, but the evidence base that governs conventional pharmaceutical approval does not yet exist. Physicians exploring MOTS-C as part of a metabolic protocol do so with reference to the published preclinical data and individual patient biomarkers — particularly fasting insulin, HbA1c, and inflammatory markers such as high-sensitivity CRP. For patients with established insulin resistance or age-related metabolic decline, it is one of several peptides a physician may consider within a broader, biomarker-guided protocol.

If you are exploring MOTS-C or metabolic peptide protocols, our clinical team can review your biomarkers and discuss whether this fits your goals — take the 2-minute quiz at /find-my-stack or book a free consultation at /book.